Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1976 Mar;9(3):406–413. doi: 10.1128/aac.9.3.406

Effect of Amphotericin B and Rifampin Against Coccidioides immitis In Vitro and In Vivo1

M Huppert *, D Pappagianis †, S H Sun †, I Gleason-Jordan †, M S Collins †, K R Vukovich †
PMCID: PMC429544  PMID: 1259400

Abstract

Amphotericin B, the principal drug used for treating systemic mycoses, possesses undesirable toxic properties. The ability of this antibiotic to potentiate antifungal activity of other compounds suggests that lower doses of amphotericin B could be used in combination with a second drug without loss of therapeutic efficacy. In vitro tests demonstrated that amphotericin B potentiated rifampin against the mycelial growth phase of Coccidioides immitis but not against the spherule-endospore phase. Therapy for murine coccidioidomycosis with a combined amphotericin B-rifampin regimen was not better than treatment with amphotericin B alone; in fact, combined drugs may have been even less effective. This would have clinical significance for therapy of concurrent infections.

Full text

PDF
406

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andreoli T. E. The structure and function of amphotericin B-cholesterol pores in lipid bilayer membranes. Ann N Y Acad Sci. 1974 May 10;235(0):448–468. doi: 10.1111/j.1749-6632.1974.tb43283.x. [DOI] [PubMed] [Google Scholar]
  2. Battaner E., Kumar B. V. Rifampin: inhibition of ribonucleic acid synthesis after potentiation by amphotericin B in Saccharomyces cerevisiae. Antimicrob Agents Chemother. 1974 Apr;5(4):371–376. doi: 10.1128/aac.5.4.371. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Beggs W. H., Sarosi G. A., Andrews F. A. Synergistic action of amphotericin B and rifampin on Candida albicans. Am Rev Respir Dis. 1974 Nov;110(5):671–673. doi: 10.1164/arrd.1974.110.5.671. [DOI] [PubMed] [Google Scholar]
  4. Block E. R., Bennett J. E. The combined effect of 5-fluorocytosine and amphotericin B in the therapy of murine cryptococcosis. Proc Soc Exp Biol Med. 1973 Feb;142(2):476–480. doi: 10.3181/00379727-142-37049. [DOI] [PubMed] [Google Scholar]
  5. Bogorad L. Evolution of organelles and eukaryotic genomes. Science. 1975 May 30;188(4191):891–898. doi: 10.1126/science.1138359. [DOI] [PubMed] [Google Scholar]
  6. Collins M. S., Pappagianis D. Inhibition by lysozyme of growth of the spherule phase of Coccidioides immitis in vitro. Infect Immun. 1974 Sep;10(3):616–623. doi: 10.1128/iai.10.3.616-623.1974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Collins M. S., Pappagianis D. Lysozyme-enhanced killing of Candida albicans and Coccidioides immitis by amphoteracin B. Sabouraudia. 1974 Nov;12(3):329–340. [PubMed] [Google Scholar]
  8. Collins S., Pappagians D. Inhibition of Coccidioides immitis in vitro and enhancement of antiococcidiodial effects of amphotericin B by polymyxin B. Antimicrob Agents Chemother. 1975 Jun;7(6):781–787. doi: 10.1128/aac.7.6.781. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. GEHAN E. A. A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES. Biometrika. 1965 Jun;52:203–223. [PubMed] [Google Scholar]
  10. Grassi G. G., Pozzi E. Effect of rifampicin on delayed-hypersensitivity reactions. J Infect Dis. 1972 Nov;126(5):542–544. doi: 10.1093/infdis/126.5.542. [DOI] [PubMed] [Google Scholar]
  11. Hamilton-Miller J. M. Chemistry and biology of the polyene macrolide antibiotics. Bacteriol Rev. 1973 Jun;37(2):166–196. [PMC free article] [PubMed] [Google Scholar]
  12. Huppert M., Sun S. H., Vukovich K. R. Combined amphotericin B-tetracycline therapy for experimental coccidioidomycosis. Antimicrob Agents Chemother. 1974 May;5(5):473–478. doi: 10.1128/aac.5.5.473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kobayashi G. S., Cheung S. S., Schlessinger D., Medoff G. Effects of rifamycin derivatives, alone and in combination with amphotericin B, against Histoplasma capsulatum. Antimicrob Agents Chemother. 1974 Jan;5(1):16–18. doi: 10.1128/aac.5.1.16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kobbayashi G. S., Medoff G., Schlessinger D., Kwan C. N., Musser W. E. Amphotericin B potentiation of rifampicin as an antifungal agent against the yeast phase of Histoplasma capsulatum. Science. 1972 Aug 25;177(4050):709–710. doi: 10.1126/science.177.4050.709. [DOI] [PubMed] [Google Scholar]
  15. Kwan C. N., Medoff G., Kobayashi G. S., Schlessinger D., Raskas H. J. Potentiation of the antifungal effects of antibiotics by amphotericin B. Antimicrob Agents Chemother. 1972 Aug;2(2):61–65. doi: 10.1128/aac.2.2.61. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. LEVINE H. B., COBB J. M., SMITH C. E. Immunity to coccidioi-domycosis induced in mice by purified spherule, arthrospore, and mycelial vaccines. Trans N Y Acad Sci. 1960 Apr;22:436–449. doi: 10.1111/j.2164-0947.1960.tb00711.x. [DOI] [PubMed] [Google Scholar]
  17. Medoff G., Comfort M., Kobayashi G. S. Synergistic action of amphotericin B and 5-fluorocytosine against yeast-like organisms. Proc Soc Exp Biol Med. 1971 Nov;138(2):571–574. doi: 10.3181/00379727-138-35943. [DOI] [PubMed] [Google Scholar]
  18. Medoff G., Kobayashi G. S., Kwan C. N., Schlessinger D., Venkov P. Potentiation of rifampicin and 5-fluorocytosine as antifungal antibiotics by amphotericin B (yeast-membrane permeability-ribosomal RNA-eukaryotic cell-synergism). Proc Natl Acad Sci U S A. 1972 Jan;69(1):196–199. doi: 10.1073/pnas.69.1.196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Newman R., Doster B. E., Murray F. J., Woolpert S. F. Rifampin in initial treatment of pulmonary tuberculosis. A.U.S. Public Health Service tuberculosis therapy trial. Am Rev Respir Dis. 1974 Feb;109(2):216–232. doi: 10.1164/arrd.1974.109.2.216. [DOI] [PubMed] [Google Scholar]
  20. Pallanza R., Arioli V., Furesz S., Bolzoni G. Rifampicin: a new rifamycin. II. Laboratory studies on the antituberculous activity and preliminary clinical observations. Arzneimittelforschung. 1967 May;17(5):529–534. [PubMed] [Google Scholar]
  21. Raleigh J. W. Rifampin in treatment of advanced pulmonary tuberculosis. Report of a VA cooperative pilot study. Am Rev Respir Dis. 1972 Mar;105(3):397–409. doi: 10.1164/arrd.1972.105.3.397. [DOI] [PubMed] [Google Scholar]
  22. Rifkind D., Crowder E. D., Hyland R. N. In vitro inhibition of Coccidioides immitis strains with amphotericin B plus rifampin. Antimicrob Agents Chemother. 1974 Dec;6(6):783–784. doi: 10.1128/aac.6.6.783. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Ruben F. L., Winkelstein A., Fotiadis I. G. Immunological responsiveness of tuberculosis patients receiving rifampin. Antimicrob Agents Chemother. 1974 Apr;5(4):383–387. doi: 10.1128/aac.5.4.383. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Schwartz S. N., Medoff G., Kobayashi G. S., Kwan C. N., Schlessinger D. Antifungal properties of polymyxin B and its potentiation of tetracycline as an antifungal agent. Antimicrob Agents Chemother. 1972 Jul;2(1):36–40. doi: 10.1128/aac.2.1.36. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Thomas M. Z., Medoff G., Kobayashi G. S. Changes in murine resistance to Listeria monocytogenes infection induced by amphotericin B. J Infect Dis. 1973 Apr;127(4):373–377. doi: 10.1093/infdis/127.4.373. [DOI] [PubMed] [Google Scholar]
  26. Titsworth E., Grunberg E. Chemotherapeutic activity of 5-fluorocytosine and amphotericin B against Candida albicans in mice. Antimicrob Agents Chemother. 1973 Sep;4(3):306–308. doi: 10.1128/aac.4.3.306. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Verbist L., Gyselen A. Antituberculous activity of rifampin in vitro and in vivo and the concentrations attained in human blood. Am Rev Respir Dis. 1968 Dec;98(6):923–932. doi: 10.1164/arrd.1968.98.6.923. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES